Cohort of Patients With Inflammatory Bowel Disease During COVID-19 Pandemic

Nantes University Hospital1,109 enrolled

Overview

Multicenter cohort of patients followed for 6 months during the pandemic in France with biocollection of sera and peripheral blood mononuclear cells

Multicenter cohort of patients followed for 6 months during the pandemic in France with biocollection of sera and peripheral blood mononuclear cellsNo data has been published concerning the incidence and prevalence of SARS-CoV-2 infection in patients with IBD and treated by IV infusion of infliximab or vedolizumab. It seems that biotherapies have a minimal impact on the severity of the viral infection but data are scarce. The objectives of the cohort are to quantify the incidence and the prevalence of SARS-CoV-2 in this population of patients, to determine clinical, demographic and biological factors associated with the risk of infection and the severity of the disease with a Multicenter cohort of patients followed for 6 months during the pandemic in France with biocollection of sera and peripheral blood mononuclear cells.

Study Type

OBSERVATIONAL

Enrollment

1,109

Conditions

IBD COVID

Eligibility

Sex: ALLMin age: 18 YearsMax age: 100 Years

Medical Language ↔ Plain English

Inclusion Criteria: * adult patients (\>18 years), know Crohn's disease or ulcerative colitis, treated by infliximab or vedolizumab Exclusion Criteria: * not affiliated to a sanitary social insurance

Locations (1)

Chu Nantes

Nantes, France

Outcomes

Primary Outcomes

IgG and IgM anti SARS-CoV-2

Impact of antibodies du to immunosuppressive protocol on the risk of viral infection

Time frame: through study completion, an average of 2 year

Secondary Outcomes

Clinical factors and severity of COVID-19 infection

Describe clinical factors of the population of IBD patients treated with vedolizumab or infliximab who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management. * weight (Kg) * height (m) * ABO Group ....

Time frame: through study completion, an average of 2 year

demographic factors and severity of COVID-19 infection

Describe demographic factors of the population of IBD patients treated with vedolizumab or infliximab who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management. * ACCOMMODATION * HOUSING AREA * number of people at home ....

Time frame: through study completion, an average of 2 year

pharmacologic factors and severity of COVID-19 infection

Describe residual rates of treatments (edolizumab or infliximab) of the population of IBD patients who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management.

Time frame: through study completion, an average of 2 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.